Floatz logo

TENATUMOMAB

Urogenital Neoplasm

sigma-tau i.f.r. S.p.A.monoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Urogenital Neoplasm cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Region Skane
Phase 4BB
Docetaxel
Sandy Srinivas
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Astellas Pharma Global Development, Inc.
Phase 2BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Eli Lilly and Company
Phase 3B
VOLITINIB
AstraZeneca
Phase 3B

View all 50 →

Same molecule, other indications

TENATUMOMAB is also rated in:

head and neck neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
skin neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
respiratory tract neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →